{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:40:43Z","timestamp":1786372843058,"version":"build-2736575974"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>\n                    Patients with CKD exhibit a disproportionate burden of cardiovascular mortality, which likely stems from the presence of unique, nontraditional risk factors that accompany deteriorating kidney function. Mounting evidence suggests that alterations to the intestinal microbiome in CKD may serve as one such risk factor. The human intestinal tract is home to &gt;100 trillion micro-organisms made up of a collection of commensal, symbiotic, and pathogenic species. These species along with their local environment constitute the intestinal microbiome. Patients with CKD show intestinal dysbiosis, an alteration of the gut micro-organism composition and function. Recent evidence links byproducts of intestinal dysbiosis to vascular calcification, atherosclerosis formation, and adverse cardiovascular outcomes in CKD. CKD-associated intestinal dysbiosis may also be accompanied by defects in intestinal barrier function, which could further enhance the negative effects of pathogenic intestinal bacteria in the human host. Thus, intestinal dysbiosis, defective intestinal barrier function, and a reduced capacity for clearance by the kidney of absorbed bacterial byproducts may all potentiate the development of cardiovascular disease in CKD. This narrative review focuses on microbiome-mediated mechanisms associated with CKD that may promote atherosclerosis formation and cardiovascular disease. It includes (\n                    <jats:italic toggle=\"yes\">1<\/jats:italic>\n                    ) new data supporting the hypothesis that intestinal barrier dysfunction leads to bacterial translocation and endotoxemia that potentiate systemic inflammation, (\n                    <jats:italic toggle=\"yes\">2<\/jats:italic>\n                    ) information on the accumulation of dietary-derived bacterial byproducts that stimulate pathways promoting atheromatous changes in arteries and cardiovascular disease, and (\n                    <jats:italic toggle=\"yes\">3<\/jats:italic>\n                    ) potential interventions. Despite great scientific interest in and a rapidly growing body of literature on the relationship between the microbiome and cardiovascular disease in CKD, many important questions remain unanswered.\n                  <\/jats:p>","DOI":"10.2215\/cjn.12691117","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T10:10:31Z","timestamp":1525860631000},"page":"1598-1604","source":"Crossref","is-referenced-by-count":64,"title":["Microbiome and Cardiovascular Disease in CKD"],"prefix":"10.2215","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02572882","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03265639","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Anna","family":"Jovanovich","sequence":"first","affiliation":[{"name":"Renal Section, Veterans Affairs Eastern Colorado Health Care System, Denver, Colorado;"},{"name":"Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Isakova","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Stubbs","sequence":"additional","affiliation":[{"name":"The Jared Grantham Kidney Institute, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2369-14-132","article-title":"Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: An analysis of national health and nutritional examination survey data, 2001-2010","volume":"14","author":"Kuznik","year":"2013","journal-title":"BMC Nephrol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1681\/ASN.2013080905","article-title":"The gut microbiome, kidney disease, and targeted interventions","volume":"25","author":"Ramezani","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41598-017-01387-y","article-title":"Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000360010","article-title":"Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD","volume":"39","author":"Wong","year":"2014","journal-title":"Am J Nephrol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1038\/s41598-017-02989-2","article-title":"Alteration of the gut microbiota in Chinese population with chronic kidney disease","volume":"7","author":"Jiang","year":"2017","journal-title":"Sci Rep"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"15601","DOI":"10.1038\/s41598-017-15650-9","article-title":"Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis","volume":"7","author":"Stadlbauer","year":"2017","journal-title":"Sci Rep"},{"key":"B8-20230813","article-title":"Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: Evidence from a randomized controlled trial [published online ahead of print November 20, 2017]","author":"Riccio","journal-title":"Clin Exp Nephrol"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/ndt\/gfx029","article-title":"Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease","volume":"32","author":"Nazzal","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1681\/ASN.2015111285","article-title":"Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation","volume":"28","author":"Andersen","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis--an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jpba.2017.11.040","article-title":"Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change","volume":"149","author":"Liu","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semnephrol.2014.02.004","article-title":"Protein-bound molecules: A large family with a bad character","volume":"34","author":"Sirich","year":"2014","journal-title":"Semin Nephrol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.numecd.2014.04.006","article-title":"Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: An observational study","volume":"24","author":"Rossi","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2215\/CJN.03980609","article-title":"Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients","volume":"4","author":"Barreto","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2215\/CJN.07971109","article-title":"p-Cresol and cardiovascular risk in mild-to-moderate kidney disease","volume":"5","author":"Meijers","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.atherosclerosis.2010.03.036","article-title":"Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure","volume":"211","author":"Wang","year":"2010","journal-title":"Atherosclerosis"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.kint.2017.05.012","article-title":"Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes","volume":"92","author":"Shafi","year":"2017","journal-title":"Kidney Int"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","article-title":"Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk","volume":"368","author":"Tang","year":"2013","journal-title":"N Engl J Med"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0006-2952(98)00218-4","article-title":"Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: Selective catalysis by FMO3","volume":"56","author":"Lang","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1681\/ASN.2014111063","article-title":"Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden","volume":"27","author":"Stubbs","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"e02481","DOI":"10.1128\/mBio.02481-14","article-title":"Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide","volume":"6","author":"Romano","year":"2015","journal-title":"MBio"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.kint.2016.01.014","article-title":"Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events","volume":"89","author":"Kim","year":"2016","journal-title":"Kidney Int"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"e0141738","DOI":"10.1371\/journal.pone.0141738","article-title":"Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease","volume":"11","author":"Missailidis","year":"2016","journal-title":"PLoS One"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCRESAHA.116.305360","article-title":"Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease","volume":"116","author":"Tang","year":"2015","journal-title":"Circ Res"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.jrn.2015.02.006","article-title":"Associations of trimethylamine N-oxide with nutritional and inflammatory biomarkers and cardiovascular outcomes in patients new to dialysis","volume":"25","author":"Kaysen","year":"2015","journal-title":"J Ren Nutr"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1681\/ASN.2016030374","article-title":"Trimethylamine o-oxide and cardiovascular events in hemodialysis patients","volume":"28","author":"Shafi","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1681\/ASN.2015121302","article-title":"Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD","volume":"27","author":"Poesen","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/ndt\/gfw009","article-title":"The influence of renal transplantation on retained microbial-human co-metabolites","volume":"31","author":"Poesen","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"e0126048","DOI":"10.1371\/journal.pone.0126048","article-title":"Free levels of selected organic solutes and cardiovascular morbidity and mortality in hemodialysis patients: Results from the retained organic solutes and clinical outcomes (ROSCO) investigators","volume":"10","author":"Shafi","year":"2015","journal-title":"PLoS One"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J Lipid Res"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1023\/A:1020575001944","article-title":"Chronic renal failure-induced changes in serum and urine bile acid profiles","volume":"47","author":"Jimenez","year":"2002","journal-title":"Dig Dis Sci"},{"key":"B35-20230813","first-page":"A14937","article-title":"Deoxycholic acid contributes to chronic kidney disease-dependent vascular calcification","volume":"128","author":"Miyazaki","year":"2013","journal-title":"Circulation"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tips.2007.03.002","article-title":"FXR: A promising target for the metabolic syndrome?","volume":"28","author":"Cariou","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCRESAHA.109.212969","article-title":"Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-\/- mice with chronic kidney disease","volume":"106","author":"Miyazaki-Anzai","year":"2010","journal-title":"Circ Res"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"e108270","DOI":"10.1371\/journal.pone.0108270","article-title":"Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis","volume":"9","author":"Miyazaki-Anzai","year":"2014","journal-title":"PLoS One"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.ajkd.2017.06.017","article-title":"Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD","volume":"71","author":"Jovanovich","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1681\/ASN.2014010042","article-title":"Randomized placebo-controlled EPPIC trials of AST-120 in CKD","volume":"26","author":"Schulman","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/07315724.2017.1334602","article-title":"Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients","volume":"36","author":"Guida","year":"2017","journal-title":"J Am Coll Nutr"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2215\/CJN.05240515","article-title":"Synbiotics easing renal failure by improving gut microbiology (SYNERGY): A randomized trial","volume":"11","author":"Rossi","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.numecd.2014.04.007","article-title":"Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: A randomized clinical trial","volume":"24","author":"Guida","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.jrn.2014.05.006","article-title":"Effects of a symbiotic on gut microbiota in Mexican patients with end-stage renal disease","volume":"24","author":"Cruz-Mora","year":"2014","journal-title":"J Ren Nutr"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.jrn.2014.09.008","article-title":"Effect of a symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin) on presence and severity of gastrointestinal symptoms in hemodialysis patients","volume":"25","author":"Viramontes-H\u00f6rner","year":"2015","journal-title":"J Ren Nutr"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"e0153893","DOI":"10.1371\/journal.pone.0153893","article-title":"The influence of prebiotic arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease: A randomized controlled trial","volume":"11","author":"Poesen","year":"2016","journal-title":"PLoS One"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.jrn.2014.09.002","article-title":"Fiber supplementation lowers plasma p-cresol in chronic kidney disease patients","volume":"25","author":"Salmean","year":"2015","journal-title":"J Ren Nutr"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2215\/CJN.00490114","article-title":"Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients","volume":"9","author":"Sirich","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201810000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:57Z","timestamp":1786369077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201810000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.12691117","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,9]]}}}